Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-257374
Filing Date
2025-10-30
Accepted
2025-10-30 06:57:30
Documents
69
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20250930.htm   iXBRL 10-Q 2948657
2 EX-10.1 apls-ex10_1.htm EX-10.1 63842
3 EX-31.1 apls-ex31_1.htm EX-31.1 18518
4 EX-31.2 apls-ex31_2.htm EX-31.2 17698
5 EX-32.1 apls-ex32_1.htm EX-32.1 10230
6 EX-32.2 apls-ex32_2.htm EX-32.2 10331
  Complete submission text file 0001193125-25-257374.txt   11272034

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apls-20250930.xsd EX-101.SCH 1320698
72 EXTRACTED XBRL INSTANCE DOCUMENT apls-20250930_htm.xml XML 2286754
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 251432124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)